IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: Of note, we also observed an increase of miR-142 levels in T cells from normal wt mice or from healthy donors that were co-cultured respectively with BM MNCs from Mir142−/−BCR-ABL mice or from BC CML patients and treated with anti-IL-6 blocking antibody (Ab) compared with those treated with IgG (Supplementary Fig. 13i, j).